Blood enzyme may reveal hidden clues in schizoaffective disorder

NCT ID NCT07673718

Completed Knowledge-focused Sponsor: Elazığ Mental Health and Diseases Hospital Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study examines whether levels of a blood enzyme called α-N-acetylgalactosaminidase differ between people with schizoaffective disorder during acute episodes and those in remission, compared to healthy individuals. The goal is to better understand the biological processes behind the condition and explore if this enzyme could serve as a marker of disease activity. Researchers will also look at how enzyme levels relate to symptom severity and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If α-N-acetylgalactosaminidase levels correlate with disease state, it could become a blood test to help track schizoaffective disorder activity.
What could go wrong: This is a small, early observational study, not a treatment trial. The enzyme may not reliably distinguish between phases or predict outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOAFFECTIVE DISORDER

Contacts and locations

Locations

Elazığ Mental Health and Diseases Hospital Psychiatry Clinic

Elâzığ, Elâzığ, 23200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.